Oppenheimer Starts CTI BioPharma (CTIC) at Outperform
Tweet Send to a Friend
Oppenheimer initiates coverage on CTI BioPharma (NASDAQ: CTIC) with an Outperform rating and a price target of $5.00.Analyst Leah Rush ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE